Sayaka Nakamura
Overview
Explore the profile of Sayaka Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozawa T, Nakamura S, Sato H, Shinzawa H, Hagihara H, Watanabe R
Anal Chem
. 2025 Jan;
97(3):1665-1672.
PMID: 39805586
This study presents a novel approach that combines thermogravimetric analysis with time-of-flight mass spectrometry (TG-TOFMS), principal component analysis (PCA), and Kendrick mass defect (KMD) analysis─referred to as TG-PCA-KMD─to investigate molecular-scale...
2.
Uemura S, Kishimoto K, Fujikawa T, Nakamura S, Kozaki A, Saito A, et al.
Pediatr Int
. 2024 Dec;
66(1):e15836.
PMID: 39692193
Background: This study aimed to evaluate whether an early elevation of absolute eosinophil count after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was associated with the development of chronic graft-versus-host disease...
3.
Sasaki K, Takeshita J, Nakamura S, Tachibana K
J Anesth
. 2024 Oct;
39(1):61-66.
PMID: 39470765
Purpose: Whether endotracheal tube (ETT) configuration (cuffed or uncuffed) influences the occurrence of respiratory adverse events (RAEs) in patients at risk remains largely unknown. We investigated the effects of cuffed...
4.
Tanaka S, Tamiya M, Nishiuma S, Nakamura S, Nozaki K, Watanabe N, et al.
Cancer Treat Res Commun
. 2024 Aug;
40:100836.
PMID: 39098310
Background: The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however...
5.
Nakamura A, Jo S, Nakamura S, Aparnathi M, Boroojeni S, Korshko M, et al.
Cell Mol Immunol
. 2024 Jun;
21(7):770-786.
PMID: 38839914
The hallmarks of spondyloarthritis (SpA) are type 3 immunity-driven inflammation and new bone formation (NBF). Macrophage migration inhibitory factor (MIF) was found to be a key driver of the pathogenesis...
6.
Fujikawa T, Uemura S, Hasegawa D, Morisada N, Nakamura S, Kozaki A, et al.
Pediatr Blood Cancer
. 2024 Mar;
71(6):e30736.
PMID: 38523246
No abstract available.
7.
Ishimura N, Inoue K, Maruyama S, Nakamura S, Kondo N
JAMA Health Forum
. 2024 Mar;
5(3):e235445.
PMID: 38427342
Importance: Chronic kidney disease (CKD) is a major public health issue, affecting 850 million people worldwide. Although previous studies have shown the association between socioeconomic status and CKD, little is...
8.
Watanabe R, Nakamura S, Sugahara A, Kishi M, Sato H, Hagihara H, et al.
Anal Chem
. 2024 Jan;
96(6):2628-2636.
PMID: 38287876
This study introduces a novel method that utilizes evolved gas analysis with time-of-flight mass spectrometry (EGA-TOFMS) coupled with principal component analysis (PCA) and Kendrick mass defect (KMD) analysis, called EGA-PCA-KMD,...
9.
Uemura S, Hasegawa D, Kishimoto K, Fujikawa T, Nakamura S, Kozaki A, et al.
Cancer Med
. 2023 Jul;
12(16):17018-17027.
PMID: 37434385
Background: The present study aimed to examine the association between the conditioning intensity and height growth in pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: We reviewed...
10.
Walsh C, Rajora M, Ding L, Nakamura S, Endisha H, Rockel J, et al.
Chem Biomed Imaging
. 2023 May;
1(1):66-80.
PMID: 37122828
Despite the substantial burden posed by osteoarthritis (OA) globally, difficult challenges remain in achieving early OA diagnosis and adopting effective disease-modifying treatments. In this study, we use a biomolecular approach...